Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R61CA263335-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
The goal of this study is to pilot test an Electronic Health Mindfulness-based Music Therapy Intervention (eMBMT) intervention to improve health-related quality of life (HRQoL) and reduce symptom burden of patients undergoing allogeneic stem cell transplantation (allo-SCT).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mindfulness-based Music Therapy (MBMT) | Experimental | Participants will be in the MBMT group for 5 months. |
|
| Mindfulness Meditation (MM) | Experimental | Participants will be in the MM group for 5 months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mindfulness-based Music Therapy (MBMT) | Behavioral | Participants will receive 8 music therapy sessions that will last approximately 60 minutes in length. A Music therapist will conduct the sessions. These sessions will be in person and/or virtual depending on patient status and the time between sessions will vary based on patient response to treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| Count of Participants Recruited | Recruitment will be measured by the count of participants successfully recruited and randomized into the study. | Baseline (T1) |
| Number of Participants Retained | Participant retention will be examined via the number of participants retained in the study. | Up to 18 months |
| Mean Number of Intervention Sessions that Participants Completed | Participant engagement will be examined via the mean number of intervention sessions completed by participants measured after the 8th (and last) intervention session which is given between 75 and 100 days post-transplant. | Up to 100 days post-transplant |
| Satisfaction Scores as Measured by Weekly Rating Satisfaction Score | Scores per item range from 0 to 5. Higher scores indicate more satisfaction. | Up to 100 days post-transplant |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Health Related Quality of Life Scores as Measures by Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT) | FACT-BMT score range 0-164, with higher scores indicating better quality of life. | Baseline (T1), up to 18 months |
| Change in Pain as Measured by patient reported outcome measures (PROMIS®) pain scale. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Frank J. Penedo, PhD | University of Miami | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Miami | Miami | Florida | 33136 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38763308 | Derived | Fleszar-Pavlovic SE, Esquives BN, Brito AE, Sia AM, Kauffman MA, Lopes M, Moreno PI, Koru-Sengul T, Gong R, Wang T, Wieder ED, Rueda-Lara M, Antoni M, Komanduri K, Lesiuk T, Penedo FJ. eHealth mindfulness-based music therapy for patients undergoing allogeneic hematopoietic stem cell transplantation: A pilot randomized controlled trial protocol. Contemp Clin Trials. 2024 Jul;142:107577. doi: 10.1016/j.cct.2024.107577. Epub 2024 May 17. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | May 23, 2026 | |
| Unrelease | May 26, 2026 | |
| Release | May 26, 2026 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Mindfulness Meditation (MM) | Behavioral | Participants will receive 8 mindfulness meditation sessions that will last approximately 60 minutes in length. These sessions will be participant led virtually. |
|
(PROMIS®) pain scale is scored on a range of 3 to 15 with higher scores indicating higher pain. |
| Baseline (T1), up to 18 months |
| Change in Fatigue as Measured by patient reported outcome measures (PROMIS®) Fatigue scale. | (PROMIS®) Fatigue scale is scored on a range of 8 to 40. Higher scores indicate higher fatigue. | Baseline (T1), up to 18 months |
| Change in Cognitive Function Scores as Measured by The Repeatable Battery for the Assessment of Neuropsychological Status. | The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scores range from 40-160 with higher scores indicating better cognitive function. | Baseline (T1), up to 18 months |
| Change in Sleep Quality Scores as Measured by Pittsburgh Sleep Quality Index | Pittsburgh Sleep Quality Index score range from 0 to 21. Higher score indicate worse sleep quality. | Baseline (T1), up to 18 months |
| Number of Days to Engraftment Measured from Infusion to Engraftment. | To measure the number of days to engraftment we will extract from the electronic medical record (EMR) days from infusion to engraftment. | Up to 18 months |
| Number of Days of Hospitalization Measured from Admission to Engraftment. | To measure the number of days of hospitalization we will extract from the electronic medical record (EMR) days of hospitalization from admission to engraftment. | Up to 18 months |
| Number of Hospital Readmissions after Hospital Discharge | To measure the number of hospital readmissions we will extract from the electronic medical record (EMR) the number of hospital readmissions from hospital discharge. | Up to 100 days |
| Number of Infections from Hospital Admission | To measure the number of infections we will extract from the electronic medical record (EMR) the number of infections from hospital admission measure up to 100 days post infusion. | up to 100 Days Post-Infusion Day |
| Change in anxiety Scores as Measured with the Generalized anxiety disorder (GAD-7) | Generalized anxiety disorder (GAD-7) range is 0 to 21; higher score is associated with more severe anxiety. | Baseline (T1), up to 18 months |
| Changes in Depression Scores as measured with the patient health questionnaire (PHQ-9) | PHQ-9 (patient health questionnaire) score range is from 0 to 27; higher score is associated with more severe depression. | Baseline (T1), up to 18 months |
| Change in Cancer-specific Distress Scores as Measured by the Impact of Events Scale-Revised | Impact of Events Scale-Revised range is 0 to 88; higher score is associated with more effect caused by events. | Baseline (T1), up to 18 months |
| Change in Serum Cortisol as Measured by ELISA | Serum cortisol levels are measured via ELISA. Serum Cortisol normal levels morning range: 10-20 mcg/dL ; afternoon range: 3-10 mcg/dL. Any values outside of the range are associated with higher stress and inflammation | Baseline (T1), up to 18 months |
| Change in Immunocompetence as Measured by Cytokines | Cytokines levels are measured in pg/mL. Any values outside of the normal range are associated with inflammation | Baseline (T1), up to 18 months |
| Change in Immunocompetence as Measured by Thymic Function | Thymic function T-cell receptor excision circles (TRECs) measured by TRECs/microliter. | Baseline (T1), up to 18 months |
| Change in Immunocompetence as Measured by Regulatory T cells | Regulatory T cells measured as cells/mm^3 | Baseline (T1), up to 18 months |
| Reset | Jun 22, 2026 |
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| May 23, 2026 | May 26, 2026 | |||
| May 26, 2026 | Jun 22, 2026 |
| ID | Term |
|---|---|
| D009190 | Myelodysplastic Syndromes |
| D015470 | Leukemia, Myeloid, Acute |
| D054198 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| D008228 | Lymphoma, Non-Hodgkin |
| ID | Term |
|---|---|
| D001855 | Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007951 | Leukemia, Myeloid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D007945 | Leukemia, Lymphoid |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D008223 | Lymphoma |
Not provided
Not provided
| ID | Term |
|---|---|
| D064866 | Mindfulness |
| ID | Term |
|---|---|
| D015928 | Cognitive Behavioral Therapy |
| D001521 | Behavior Therapy |
| D011613 | Psychotherapy |
| D004191 | Behavioral Disciplines and Activities |
Not provided
Not provided